The IPO of Yefeng pharmaceutical was terminated: Yu Feng, the actual controller who had planned to raise 540million yuan, made P2P investment

RedI network Lei Jianping 6 month 26 Reported Wednesday

Zhejiang Yefeng Pharmaceutical Co., Ltd （ abbreviation ：“ Yefeng pharmaceutical ”） recently IPO Terminated . Yefeng pharmaceutical had planned to raise money 5.4 One hundred million yuan .

Yefeng pharmaceutical was founded in 1996 year , It belongs to Yefeng group , The company is located in the industrial zone of Geshan Town, Dongyang City, Zhejiang Province , Located next to Zhuyong expressway .

The main business of Yefeng pharmaceutical is the research and development of characteristic APIs and pharmaceutical intermediates 、 Production and marketing , The products are based on DOPA APIs , Xiang Fen Jing API 、 Expansion of statins .

Yefeng pharmaceutical mainly includes methyldopa 、 l-dopa 、 Cabidopa 、 Characteristic APIs and intermediates such as caspofungin acetate , The main areas of medication are antihypertensive drugs, especially drugs for the treatment of pregnancy induced hypertension and renal hypertension 、 Antiparkinsonian drugs 、 Antifungal drugs, etc .

The prospectus shows , Yefeng pharmaceutical 2018 year 、2019 year 、2020 The annual revenue is 2.83 One hundred million yuan 、3.82 One hundred million yuan 、3.62 One hundred million yuan ; The net profit is respectively 3276 Ten thousand yuan 、6555 Ten thousand yuan 、8587 Ten thousand yuan ; The net profit after deducting non profits is 2777 Ten thousand yuan 、6766 Ten thousand yuan 、7912 Ten thousand yuan .

Yefeng pharmaceutical 2021 The revenue in the first half of the year is 1.75 One hundred million yuan , Net profit 3599 Ten thousand yuan , The net profit after deduction is 3515 Ten thousand yuan .

IPO front , The shares held by Yefeng group are 46.53%, For the controlling shareholder of the company ; Yu Feng passed the Yefeng group 、 Yefeng venture capital 、 Yefeng holdings indirectly controls Yefeng pharmaceutical 68.83% Equity of , Actual controller of the company .

The actual controller of the company, Yu Fen, was in “P2P” Invest in the field , It is the largest shareholder of jinmaisui finance , The shareholding ratio is 51.52%,2018 In, he was dismissed due to the relevant requirements of the state .2018 year 6 Month begins , To 2019 year 12 During the month of clearance , Yefeng group, the controlling shareholder of Yefeng pharmaceutical, is “P2P” Platform advance 2.45 One hundred million yuan .

Yefeng group “P2P” The funds advanced by the platform mainly come from several sectors ：1, Yefeng group sold its shares in Bank of Hangzhou , get 1.5 One hundred million yuan ;2, Financial support provided by Yefeng real estate, a subsidiary of Yefeng group , Wild wind property 2020 year 8 month 27 Call Ye Feng Group on the th 1.7 One hundred million yuan ;3, Bank loans .

Other shareholders of Yefeng pharmaceutical include ： The shareholding of Biyuan investment is 18.97%, Zhouweiguo holds shares of 4.35%, Tangzhaohui holds shares of 3.75%.

———————————————

Lei Di was founded by Lei Jianping, a senior media person , If reproduced, please indicate the source .